HOWL Intrinsic Valuation and Fundamental Analysis - Werewolf Therapeutics Inc - Alpha Spread

Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 2.37 USD 6.76% Market Closed
Market Cap: 103m USD
Have any thoughts about
Werewolf Therapeutics Inc?
Write Note

Intrinsic Value

HOWL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one HOWL stock under the Base Case scenario is 1.21 USD. Compared to the current market price of 2.37 USD, Werewolf Therapeutics Inc is Overvalued by 49%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HOWL Intrinsic Value
1.21 USD
Overvaluation 49%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Werewolf Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HOWL based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about HOWL?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Werewolf Therapeutics Inc

Provide an overview of the primary business activities
of Werewolf Therapeutics Inc.

What unique competitive advantages
does Werewolf Therapeutics Inc hold over its rivals?

What risks and challenges
does Werewolf Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Werewolf Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Werewolf Therapeutics Inc.

Provide P/S
for Werewolf Therapeutics Inc.

Provide P/E
for Werewolf Therapeutics Inc.

Provide P/OCF
for Werewolf Therapeutics Inc.

Provide P/FCFE
for Werewolf Therapeutics Inc.

Provide P/B
for Werewolf Therapeutics Inc.

Provide EV/S
for Werewolf Therapeutics Inc.

Provide EV/GP
for Werewolf Therapeutics Inc.

Provide EV/EBITDA
for Werewolf Therapeutics Inc.

Provide EV/EBIT
for Werewolf Therapeutics Inc.

Provide EV/OCF
for Werewolf Therapeutics Inc.

Provide EV/FCFF
for Werewolf Therapeutics Inc.

Provide EV/IC
for Werewolf Therapeutics Inc.

Show me price targets
for Werewolf Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Werewolf Therapeutics Inc?

How accurate were the past Revenue estimates
for Werewolf Therapeutics Inc?

What are the Net Income projections
for Werewolf Therapeutics Inc?

How accurate were the past Net Income estimates
for Werewolf Therapeutics Inc?

What are the EPS projections
for Werewolf Therapeutics Inc?

How accurate were the past EPS estimates
for Werewolf Therapeutics Inc?

What are the EBIT projections
for Werewolf Therapeutics Inc?

How accurate were the past EBIT estimates
for Werewolf Therapeutics Inc?

Compare the revenue forecasts
for Werewolf Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Werewolf Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Werewolf Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Werewolf Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Werewolf Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Werewolf Therapeutics Inc with its peers.

Analyze the financial leverage
of Werewolf Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Werewolf Therapeutics Inc.

Provide ROE
for Werewolf Therapeutics Inc.

Provide ROA
for Werewolf Therapeutics Inc.

Provide ROIC
for Werewolf Therapeutics Inc.

Provide ROCE
for Werewolf Therapeutics Inc.

Provide Gross Margin
for Werewolf Therapeutics Inc.

Provide Operating Margin
for Werewolf Therapeutics Inc.

Provide Net Margin
for Werewolf Therapeutics Inc.

Provide FCF Margin
for Werewolf Therapeutics Inc.

Show all solvency ratios
for Werewolf Therapeutics Inc.

Provide D/E Ratio
for Werewolf Therapeutics Inc.

Provide D/A Ratio
for Werewolf Therapeutics Inc.

Provide Interest Coverage Ratio
for Werewolf Therapeutics Inc.

Provide Altman Z-Score Ratio
for Werewolf Therapeutics Inc.

Provide Quick Ratio
for Werewolf Therapeutics Inc.

Provide Current Ratio
for Werewolf Therapeutics Inc.

Provide Cash Ratio
for Werewolf Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Werewolf Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Werewolf Therapeutics Inc?

What is the current Free Cash Flow
of Werewolf Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Werewolf Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Werewolf Therapeutics Inc

Current Assets 138.8m
Cash & Short-Term Investments 135.3m
Receivables 545k
Other Current Assets 2.9m
Non-Current Assets 14.9m
PP&E 13.4m
Other Non-Current Assets 1.5m
Current Liabilities 11.4m
Accounts Payable 1.5m
Accrued Liabilities 10m
Non-Current Liabilities 38.2m
Long-Term Debt 25.2m
Other Non-Current Liabilities 13.1m
Efficiency

Earnings Waterfall
Werewolf Therapeutics Inc

Revenue
9.3m USD
Operating Expenses
-67.6m USD
Operating Income
-58.3m USD
Other Expenses
4.6m USD
Net Income
-53.7m USD

Free Cash Flow Analysis
Werewolf Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HOWL Profitability Score
Profitability Due Diligence

Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
ROIC is Increasing
Negative 1-Year Revenue Growth
Negative Revenue Growth Forecast
19/100
Profitability
Score

Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

HOWL Solvency Score
Solvency Due Diligence

Werewolf Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
52/100
Solvency
Score

Werewolf Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HOWL Price Targets Summary
Werewolf Therapeutics Inc

Wall Street analysts forecast HOWL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOWL is 12.24 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

Lowest
Price Target
8.08 USD
241% Upside
Average
Price Target
12.24 USD
416% Upside
Highest
Price Target
15.75 USD
565% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HOWL?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for HOWL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about HOWL dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

HOWL Price
Werewolf Therapeutics Inc

1M 1M
+9%
6M 6M
-60%
1Y 1Y
-7%
3Y 3Y
-86%
5Y 5Y
-85%
10Y 10Y
-85%
Annual Price Range
2.37
52w Low
1.71
52w High
7.91
Price Metrics
Average Annual Return -53.43%
Standard Deviation of Annual Returns 42.14%
Max Drawdown -92%
Shares Statistics
Market Capitalization 103.6m USD
Shares Outstanding 43 460 000
Percentage of Shares Shorted 4.15%

Competitive Landscape

Ownership

HOWL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

103.6m USD

Dividend Yield

0%

Description

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

Contact

MASSACHUSETTS
Cambridge
1030 Massachusetts Avenue, Suite 210
+16179520555.0
werewolftx.com

IPO

2021-04-30

Employees

39

Officers

See Also

Discover More
What is the Intrinsic Value of one HOWL stock?

The intrinsic value of one HOWL stock under the Base Case scenario is 1.21 USD.

Is HOWL stock undervalued or overvalued?

Compared to the current market price of 2.37 USD, Werewolf Therapeutics Inc is Overvalued by 49%.

Back to Top